Inna Salisbury
Payments from drug & device makers
Across 53 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$184
- Boehringer Ingelheim$125
- AbbVie$112
- Bayer$99
- Pfizer$81
- Shield Therapeutics Inc$76
- plus $391 from 15 others
What the payments were for
- Food & beverage$1,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $184 |
| Boehringer Ingelheim | 1 | $125 |
| AbbVie | 7 | $112 |
| Bayer | 5 | $99 |
| Pfizer | 5 | $81 |
| Shield Therapeutics Inc | 4 | $76 |
| Gilead | 3 | $73 |
| Exact Sciences | 3 | $42 |
| Insulet Corporation | 2 | $37 |
| Lilly USA, LLC | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Medtronic | 1 | $28 |
| Electromed, Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Grifols USA, LLC | 1 | $13 |
| Merck | 1 | $13 |
| Amgen | 1 | $12 |
How this compares
$1,068 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 54 | $38,909 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $35,009 |
| JardianceEmpagliflozin | 31 | $24,967 |
| OzempicSemaglutide | 22 | $20,670 |
| JanuviaSitagliptin Phosphate | 22 | $15,942 |
| TrulicityDulaglutide | 12 | $11,414 |
| EliquisApixaban | 17 | $10,721 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,532 |
| XareltoRivaroxaban | 11 | $5,829 |
| VascepaIcosapent Ethyl | 19 | $5,370 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $3,179 |
| Omeprazole | 183 | $1,679 |
| Levothyroxine Sodium | 147 | $1,293 |
| Atorvastatin Calcium | 229 | $1,201 |
| Metoprolol Succinate | 58 | $1,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $184 | $41,54173 claims |
| AstraZenecaFarxiga | $13 | $38,90954 claims |
| Boehringer IngelheimJardiance | $125 | $24,96731 claims |
| MerckJanuvia | $13 | $15,94222 claims |
| Lilly USA, LLCTrulicity | $31 | $11,41412 claims |
| PfizerEliquis | $81 | $10,72117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.
Other family in Utica
- Jenna PawloskiUtica$62K
- Nicolette HaleyUtica$19K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.